Loading...
•
Jun 30, 2020
Harrow Q2 2020 Earnings Report
Reported results for the second quarter 2020.
Key Takeaways
Harrow Health reported its results for the second quarter of 2020, noting that the impact from COVID-19 was substantial for a limited period, but the segments of the economy that are most relevant to their success recovered rapidly and are now at near-normal levels.
The company made great progress during a challenging second quarter.
The impact from COVID-19 was substantial for a limited period, but the segments of the economy that are most relevant to the company's success recovered rapidly and are now at near-normal levels.
The company is seeing trends of record-high revenue days into the third quarter as the economy and healthcare providers continue to make a strong comeback.
The company announced a partnership with EyePoint Pharmaceuticals to market FDA-approved DEXYCU®.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...